Manfredi R, Mastroianni A, Coronado O, Vezzadini P, Fanti MP, Chiodo F; International Conference on AIDS.
Int Conf AIDS. 1994 Aug 7-12; 10: 188 (abstract no. PB0179).
University of Bologna, Italy.
OBJECTIVE. We have previously described 3 AIDS patients (p) with chronic idiopathic diarrhea associated with elevated vasoactive intestinal peptide (VIP) secretion (AIDS 1993; 7:223-6). Aim of this study is to evaluate a series of AIDS/ARC p with intractable infectious and noninfectious diarrhea. METHODS AND RESULTS. Elevated plasma levels of VIP (as assessed by a radio-immunoassay) were found in 4/6 p with prolonged intractable cryptosporidial diarrhea (mean 13.9 +/- 2.2 pmol/l), and in 3/5 p with idiopathic diarrhea (mean 12.8 +/- 4.2 pmol/l), while a control group of 12 AIDS/ARC p without gastrointestinal disorders showed normal VIP levels (mean 4.4 +/- 2.3 pmol/l; n.v. < 8.8 pmol/l). Six p (3 with infectious diarrhea and 3 with idiopathic disease) were treated with the somatostatin analogue octreotide (100-300 micrograms/day s.c.) over a mean period of 12.2 +/- 8.7 weeks, showing remission of the intestinal picture in all pts, associated with a relevant reduction of plasma VIP concentrations, comparing with pretreatment values (from a mean level of 11.9 +/- 3.3 to 7.2 +/- 3.5 pmol/l; p < .001, Student t test for paired data). CONCLUSIONS. Both infectious and non-infectious refractory HIV-related diarrhea show a frequent association with elevated VIP levels, corrected by octreotide administration. Assessment of VIP secretion may provide a pathophysiological rationale for recognizing in advance pts with intractable diarrhea who may present a better clinical response to octreotide treatment.
Publication Types:
Keywords:
- AIDS-Related Complex
- Acquired Immunodeficiency Syndrome
- Diarrhea
- Dysentery
- HIV Seropositivity
- Humans
- Octreotide
- Somatostatin
- Vasoactive Intestinal Peptide
Other ID:
UI: 102208453
From Meeting Abstracts